First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

BACKGROUND: Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-E...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Kathryn E., Keefer, Michael C., Bunce, Catherine A., Frances, Doreen, Abbink, Peter, Maxfield, Lori F., Neubauer, George H., Nkolola, Joseph, Peter, Lauren, Lane, Christopher, Park, Harriet, Verlinde, Carl, Lombardo, Angela, Yallop, Christopher, Havenga, Menzo, Fast, Patricia, Treanor, John, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235250/
https://www.ncbi.nlm.nih.gov/pubmed/30427829
http://dx.doi.org/10.1371/journal.pone.0205139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235250/
https://www.ncbi.nlm.nih.gov/pubmed/30427829
http://dx.doi.org/10.1371/journal.pone.0205139

Ejemplares similares